港股異動 | 海普瑞H股午後一度漲超4%,獲FDA批準成依諾肝素製劑供應商
uSMART友信智投9月23日消息,海普瑞午後直線拉昇,一度漲4.7%。
9月21日,海普瑞(002399.SZ)(9989.HK)發佈公告,其全資子公司天道醫藥已經獲得美國FDA批準,成爲一家美國依諾肝素鈉製劑上市許可持有人的藥品以及原料藥的供應商,這將有助於公司在美國市場上的佈局,全球化戰略更進一步。
西南證券發佈研報稱,海普瑞成功進入美國市場,有望享受規範市場的成長份額。預計2020-2022年歸母淨利潤分別爲10.2億元、12.8億元、15.4億元,考慮到股本變化對應EPS爲0.70、0.87、1.05元,對應PE爲33、26、22倍。公司肝素原料藥和製劑一體化,大分子CDMO+創新藥打開成長空間,維持“買入”評級。
長城證券發佈研報稱,預計公司2020-2022年營業收入分別爲59.14億元、67.89億元和77.18億元,同比增速27.9%、14.8%和13.7%,歸母淨利潤分別爲10.72億元、13.22億元和15.89億元,同比增速爲1.2%、23.3%和20.2%,EPS 分別爲0.73/0.90/1.08元,對應9月21日收盤價,對應市盈率分別爲31X、25X、21X,維持"強烈推薦"評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.